Modulation of Lamina Cribrosa Matrix Remodeling in POAG
Principal Investigator
Colm O'Brien, MD, FRCS
Mater Misericordiae Hospital (Ireland)
Dublin, Ireland
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
G2007051
Goals
This project intends to test the hypothesis of that the use of novel anti-fibrotic therapies will reduce the damage done in glaucoma to the retinal ganglion cells thereby alleviating the resultant loss of vision.
Summary
At present, glaucoma represents the most common form of irreversible blindness in the western world. The exact causes of the different types of glaucoma are not fully understood but in one common form, primary open angle glaucoma it is believed that mechanical strain induced by elevated intra-ocular pressure plays a part. This causes changes in the connective tissue of the lamina cribrosa, which is where the optic nerves exit the eye. Previous evidence has shown that soluble growth factors such as the TGF- family can affect the extracellular composition of this tissue. By modulating the expression of the TGF- family we hope to change the connective tissue composition of the lamina cribrosa and thereby reduce the damage to the retinal ganglion cells and reduce loss of visual function.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute